Biohybrid Devices and Encapsulation Technologies for Engineering a Bioartificial Pancreas

Cell Transplantation

Review

Nicholas Fort¹  Alexander Fort¹  Cherie L. Stabler²  Camillo Ricordi³ 

[1] Diabetes Research Institute, University of Miami, Miami, FL, USA;Diabetes Research Institute, University of Miami, Miami, FL, USA; Department of Surgery, University of Miami, Miami, FL, USA; Department of Biomedical Engineering, University of Miami, Miami, FL, USA;Diabetes Research Institute, University of Miami, Miami, FL, USA; Department of Surgery, University of Miami, Miami, FL, USA; Department of Biomedical Engineering, University of Miami, Miami, FL, USA; Karolinska Institute, Stockholm, Sweden; Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA;

关键词: Diabetes;    Bioartificial pancreas;    Biohybrid device;    Encapsulation;   

DOI  :  10.3727/096368908786991498

 received in 2008-01-09, accepted in 2008-05-06,  发布年份 2008

来源: Sage Journals

【 摘 要 】

The use of cell-based treatments in the field of metabolic organs, particularly the pancreas, has seen tremendous growth in recent years. The transplantation of islet of Langerhans cells for the treatment of type 1 diabetes mellitus (T1DM) has allowed for natural glycemic control for patients plagued with hypoglycemia unawareness. The transplantation of islet cells into the portal vein of the liver, however, has presented challenges to the survival of the cells due to inflammation, vascularization, the need for systemic immunosuppression, and physical stress on the graft. New advances in the engineering of appropriate biohybrid devices and encapsulation technologies have led to promising alternatives to traditional methods.

【 授权许可】

Unknown   
© 2008 Cognizant Comm. Corp.